| Ticker: | AKBA |
| Current Price: | $0.47 |
| % Daily Change: | -4.78% |
| Volume (1,000s): | 3,880.94 |
| Average Volume (1,000s): | 5,064.80 |
| Market Cap (M): | $131.67 |
| 1/2/2024 Price: | $1.27 |
| Change Since Inception: | -62.99% |
Akebia Therapeutics, Inc.
245 First Street
Suite 1400
Cambridge, MA 02142
United States
Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease.
Since our founding in 2007, we’ve put tenacity and innovation to work to develop unique therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal community. Today, we are a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization. We currently have two FDA-approved products.